ConGen, a biotechnology enterprise founded by a group of biologists including Mari Carmen Garrido Navas, has emerged as a significant player in the realm of personalized medicine using genetic insights. Established in Alcalá la Real, Jaén, ConGen was catalyzed by the opportunities presented in the genetics field, especially highlighted during the pandemic. The company focuses on preventive healthcare measures and improving treatment efficacy, catering to a growing need for personalized health solutions.

In just four years since its establishment, ConGen has received notable accolades, including a spot in the Top Spain Up Nation, recognizing it as one of the most innovative young companies in Spain. This honor, awarded by Enisa, underscores the company's commitment to bridging the gap between advanced genetic research and practical medical applications. Their innovative approach not only aims to enhance health outcomes for individuals but also positions them on the cutting edge of the biotechnology landscape in Spain.

ConGen's business model shows promise, with a revenue of over 150,000 euros in the past year, and ambitious plans to triple this figure in the upcoming three years. This trajectory reflects the increasing demand for personalized medicine solutions and the potential growth of biotech firms that leverage genetic advancements, paving the way for more targeted and effective treatments in healthcare.